ClinicalTrials.gg
RecruitingNCT07038434RUGGIUpdated Jun 26, 2025

Refining mUltiple Artificial intelliGence strateGies for Automatic Pain Assessment Investigations: RUGGI Study

An interventional study of Multimodal AI-Based Pain Assessment in Chronic Pain, Cancer Pain and Neuropathic Pain, sponsored by Valentina Cerrone. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-26.

Sponsored by Valentina Cerrone · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 65 studies in Chronic Pain with a site in Italy — 19 open to participants now, 22 under way, none of them phase 3. Chronic Pain · Italy.

Planned enrollment
12th of 40
200 · median 73
Started
2025
with 9 others
No phase
27 of 65
8 open now
Primary completion
2025-12
later than 8 of 21 live
Registered
54th of 65
by date

Among the 65 studies in Chronic Pain with a site in Italy, this one is the 12th largest by planned enrollment of the 40 interventional ones that give a count, is one of 10 that started in 2025, is one of 27 with no phase, reaches primary completion later than 8 of the 21 other live ones, and was the 54th registered.

Chronic Pain

3,230 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.

Browse Chronic Pain studies →

Open to participants now

19 of the 65 studies in Chronic Pain with a site in Italy are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies in Chronic Pain with a site in Italy, or all of them as a file.
02

Study summary

This single-center, non-profit, observational-interventional study aims to develop artificial intelligence (AI) models for the automatic assessment of chronic pain (APA - Automatic Pain Assessment). The study will enroll adult patients with chronic pain of various origins (oncologic and non-oncologic). Participants will undergo multidimensional evaluations that include clinical assessments, self-report questionnaires, bio-signal collection (e.g., EEG, EDA, HRV, GSR, PPG), and facial expression analysis via infrared thermography and video recordings.

The primary objective is to calibrate and test machine learning and deep learning models to recognize and predict the presence and severity of pain using multimodal data inputs. Secondary objectives include evaluating the effectiveness of pain treatments, assessing quality of life, and developing a standardized APA dataset for future research.

All data collection procedures are non-invasive and safe, and include tools like wearable sensors and standardized neurocognitive tests. The study is approved by the Italian Ethics Committee (Comitato Etico Territoriale Campania 2) and complies with GDPR and EU AI regulations.

Read the detailed description

This study, titled "Refining mUltiple artificial intelliGence strateGies for automatic pain assessment Investigations" (RUGGI), explores the integration of AI in chronic pain evaluation. Pain is a multidimensional and subjective experience, and conventional assessment methods often rely solely on self-reported scales. This introduces the risk of over- or under-treatment. To overcome this limitation, the study leverages multimodal data-including physiological signals, facial expressions, and linguistic analysis-to build models capable of objectively assessing pain intensity and characteristics.

The primary aim is to calibrate predictive models (e.g., Support Vector Machines, Random Forest, Convolutional Neural Networks, YOLO architectures, and MLPs) that can recognize pain patterns using supervised and unsupervised learning. Bio-signals (EEG, HRV, GSR, EMG), infrared thermography (HIRA system), and prosodic-linguistic features will be analyzed. Data will be collected during structured timepoints: baseline (rest), Stroop test execution, and follow-up.

Patients are recruited based on chronic pain diagnosis per IASP and ICD-11 criteria. Inclusion criteria include age ≥18 and informed consent. The study foresees a target enrollment of approximately 200 patients within 6 months. Data will be processed following a rigorous AI pipeline, including preprocessing, feature extraction, dimensionality reduction, and cross-validation (k-fold with grid search optimization). Outcome measures include the Area Under the Curve (AUC), sensitivity, specificity, F1 score, and model explainability (via SHAP, LIME).

Secondary outcomes include assessing patient-reported quality of life, evaluating analgesic strategies, and generating a public-use APA dataset. All procedures are compliant with Good Clinical Practice (GCP), GDPR, and EU Artificial Intelligence Act (Reg. 2024/1689). The study is conducted at the University Hospital "San Giovanni di Dio e Ruggi d'Aragona" in Salerno, Italy.

03

Conditions studied

  • Chronic Pain
  • Cancer Pain
  • Neuropathic Pain
  • Pain Assessment

Keywords

  • Artificial Intelligence
  • Machine Learning
  • Deep Learning
  • Automatic Pain Assessment
  • Facial Expression Analysis
  • Natural Language Processing
  • Stroop Test
  • Bio-signals
  • Chronic Pain
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults (≥18 years old) with chronic pain, defined according to IASP and ICD-11 as pain that persists or recurs for more than three months.
  • Diagnosed with either:
  • Chronic primary pain (e.g., fibromyalgia, irritable bowel syndrome, chronic headaches)
  • Chronic secondary non-cancer pain (e.g., low back pain, osteoarthritis, post-surgical pain)
  • Chronic cancer-related pain (due to cancer or its treatment)
  • Ability to understand the study procedures and provide written .

Exclusion criteria

Exclusion Criteria:

  • Current treatment with psychotropic drugs or presence of active psychiatric disorders (e.g., psychosis, major depression).
  • Known history of alcohol or substance abuse.
  • Pregnancy or breastfeeding.
  • Age under 18 years.
  • Inability to provide (e.g., due to cognitive impairment).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    AI-Based Pain Assessment in Chronic Pain Patients

    Participants with chronic pain will undergo a multimodal, non-invasive diagnostic assessment including self-reported pain questionnaires (NRS, DN-4, BPI), wearable biosignal acquisition (EEG, EMG, EDA, HRV), facial thermography using the HIRA system, video-based facial expression analysis, linguistic evaluation, and the Stroop Test. These data will be used to develop and validate machine learning models for automatic pain assessment.

    Diagnostic Test: Multimodal AI-Based Pain Assessment

Interventions

  • Diagnostic testMultimodal AI-Based Pain Assessment

    A non-invasive, multimodal diagnostic procedure combining self-reported pain scales (NRS, DN-4, BPI), wearable biosignal acquisition (EDA, EMG, HRV, EEG), facial thermography (HIRA system), video-based facial expression analysis, linguistic interview, and the Stroop Test. Data are used to train and validate machine learning models for automatic pain assessment in chronic pain patients.

    Also known as: Automatic Pain Assessment, AI Pain Evaluation

06

What researchers measure

Primary outcomes

  1. Accuracy of AI models in classifying chronic pain

    Accuracy will be calculated to evaluate how well supervised machine learning and deep learning models can correctly classify the presence of chronic pain using multimodal data (e.g., biosignals, facial thermography, video, and audio).

    Time frame: From Day 0 (baseline) to Day 30 (follow-up)

  2. Sensitivity of AI models in classifying chronic pain

    Sensitivity (true positive rate) will be computed to determine the model's ability to correctly identify patients experiencing chronic pain. Unit of measure: Sensitivity (%)

    Time frame: From Day 0 to Day 30

  3. Specificity of AI models in classifying chronic pain

    Specificity (true negative rate) will be computed to assess the model's ability to correctly identify patients who are not experiencing chronic pain. Unit of measure: Specificity (%)

    Time frame: From Day 0 to Day 30

  4. Precision of AI models in classifying chronic pain

    Precision (positive predictive value) will be calculated to assess the proportion of correct positive predictions among all positive classifications. Unit of measure: Precision (%)

    Time frame: From Day 0 to Day 30

  5. F1-score of AI models in classifying chronic pain

    F1-score, the harmonic mean of precision and sensitivity, will be used to assess overall model performance, especially in the presence of class imbalance. Unit of measure: F1-score (numeric value)

    Time frame: From Day 0 to Day 30

  6. AUC-ROC of AI models in classifying chronic pain

    The area under the receiver operating characteristic curve (AUC-ROC) will be used to evaluate the model's ability to discriminate between pain and no-pain conditions across thresholds. Unit of measure: AUC-ROC (numeric value from 0 to 1)

    Time frame: From Day 0 to Day 30

Secondary outcomes

  1. Change in Patient Global Impression of Change (PGIC) score

    This outcome will measure patients' perceived improvement in their condition using the PGIC scale. Unit of measure: Score on a 7-point Likert scale (1 = No change to 7 = Very much improved)

    Time frame: From Day 0 to Day 30

  2. Change in Brief Pain Inventory (BPI) interference score

    This outcome will measure how much pain interferes with daily functioning, using the BPI interference subscale. Unit of measure: Score from 0 (no interference) to 10 (complete interference)

    Time frame: From Day 0 to Day 30

  3. Correlation between analgesic treatments and pain intensity (NRS)

    The outcome will assess the correlation between the type and frequency of analgesic treatments and changes in pain intensity, measured with the Numeric Rating Scale (NRS). Unit of measure: Pearson correlation coefficient (r), NRS scores from 0 to 10

    Time frame: From Day 0 to Day 30

Other outcomes

  1. Creation of a structured multimodal dataset for AI-based pain research

    A standardized and anonymized dataset will be developed from collected multimodal inputs (biosignals, thermography, facial videos, linguistic data, questionnaires) to enable future research. Unit of measure: Dataset availability (Yes/No)

    Time frame: From Day 0 to Day 30

07

Study locations

1 of 1 sites recruiting
  • Azienda Ospedaliera Universitaria San Giovanni di Dio e Ruggi d'Aragona
    Salerno, Italy 84131, Italy
    Recruiting
    • Marco Cascella, MD, PhD · Contactmcascella@unisa.it · +39 089672428
    • Valentina Cerrone, RN, MSc · Contactvalentina.cerrone@sangiovannieruggi.it
    • Marco Cascella, MD, PhD · Principal investigator
    • Valentina Cerrone · Sub investigator
    • Giuseppe Polese · Sub investigator
    • Ornella Piazza · Sub investigator
    • Francesco Amato · Sub investigator
    • Maria Romano · Sub investigator
    • Alfonso Maria Ponsiglione · Sub investigator
    • Francesco Di Salle · Sub investigator
08

References and documents

Publications

  • Treede RD, Rief W, Barke A, Aziz Q, Bennett MI, Benoliel R, Cohen M, Evers S, Finnerup NB, First MB, Giamberardino MA, Kaasa S, Korwisi B, Kosek E, Lavand'homme P, Nicholas M, Perrot S, Scholz J, Schug S, Smith BH, Svensson P, Vlaeyen JWS, Wang SJ. Chronic pain as a symptom or a disease: the IASP Classification of Chronic Pain for the International Classification of Diseases (ICD-11). Pain. 2019 Jan;160(1):19-27. doi: 10.1097/j.pain.0000000000001384. PubMed 30586067 ↗
  • Cascella M, Di Gennaro P, Crispo A, Vittori A, Petrucci E, Sciorio F, Marinangeli F, Ponsiglione AM, Romano M, Ovetta C, Ottaiano A, Sabbatino F, Perri F, Piazza O, Coluccia S. Advancing the integration of biosignal-based automated pain assessment methods into a comprehensive model for addressing cancer pain. BMC Palliat Care. 2024 Aug 3;23(1):198. doi: 10.1186/s12904-024-01526-z. PubMed 39097739 ↗
  • Machova K, Szaboova M, Paralic J, Micko J. Detection of emotion by text analysis using machine learning. Front Psychol. 2023 Sep 20;14:1190326. doi: 10.3389/fpsyg.2023.1190326. eCollection 2023. PubMed 37799520 ↗
  • Albashayreh A, Bandyopadhyay A, Zeinali N, Zhang M, Fan W, Gilbertson White S. Natural Language Processing Accurately Differentiates Cancer Symptom Information in Electronic Health Record Narratives. JCO Clin Cancer Inform. 2024 Aug;8:e2300235. doi: 10.1200/CCI.23.00235. PubMed 39116379 ↗
  • Lotsch J, Ultsch A, Mayer B, Kringel D. Artificial intelligence and machine learning in pain research: a data scientometric analysis. Pain Rep. 2022 Nov 3;7(6):e1044. doi: 10.1097/PR9.0000000000001044. eCollection 2022 Nov-Dec. PubMed 36348668 ↗
  • Cascella M, Schiavo D, Cuomo A, Ottaiano A, Perri F, Patrone R, Migliarelli S, Bignami EG, Vittori A, Cutugno F. Artificial Intelligence for Automatic Pain Assessment: Research Methods and Perspectives. Pain Res Manag. 2023 Jun 28;2023:6018736. doi: 10.1155/2023/6018736. eCollection 2023. PubMed 37416623 ↗
  • Nicholas MK. The biopsychosocial model of pain 40 years on: time for a reappraisal? Pain. 2022 Nov 1;163(Suppl 1):S3-S14. doi: 10.1097/j.pain.0000000000002654. No abstract available. PubMed 36252231 ↗
  • Kutafina E, Becker S, Namer B. Measuring pain and nociception: Through the glasses of a computational scientist. Transdisciplinary overview of methods. Front Netw Physiol. 2023 Feb 10;3:1099282. doi: 10.3389/fnetp.2023.1099282. eCollection 2023. PubMed 36926544 ↗
  • Lang VA, Lundh T, Ortiz-Catalan M. Mathematical and Computational Models for Pain: A Systematic Review. Pain Med. 2021 Dec 11;22(12):2806-2817. doi: 10.1093/pm/pnab177. PubMed 34051102 ↗
  • Kaplan CM, Kelleher E, Irani A, Schrepf A, Clauw DJ, Harte SE. Deciphering nociplastic pain: clinical features, risk factors and potential mechanisms. Nat Rev Neurol. 2024 Jun;20(6):347-363. doi: 10.1038/s41582-024-00966-8. Epub 2024 May 16. PubMed 38755449 ↗
  • Clauw DJ. From fibrositis to fibromyalgia to nociplastic pain: how rheumatology helped get us here and where do we go from here? Ann Rheum Dis. 2024 Oct 21;83(11):1421-1427. doi: 10.1136/ard-2023-225327. PubMed 39107083 ↗
  • Cohen SP, Vase L, Hooten WM. Chronic pain: an update on burden, best practices, and new advances. Lancet. 2021 May 29;397(10289):2082-2097. doi: 10.1016/S0140-6736(21)00393-7. PubMed 34062143 ↗
  • Rahman S, Kidwai A, Rakhamimova E, Elias M, Caldwell W, Bergese SD. Clinical Diagnosis and Treatment of Chronic Pain. Diagnostics (Basel). 2023 Dec 18;13(24):3689. doi: 10.3390/diagnostics13243689. PubMed 38132273 ↗
  • Zimmer Z, Fraser K, Grol-Prokopczyk H, Zajacova A. A global study of pain prevalence across 52 countries: examining the role of country-level contextual factors. Pain. 2022 Sep 1;163(9):1740-1750. doi: 10.1097/j.pain.0000000000002557. Epub 2021 Dec 15. PubMed 35027516 ↗

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared due to the sensitive nature of biometric and video-derived data, including facial thermography and audio recordings. Although all data are anonymized, there remains a potential risk of re-identification through multimodal signals. Additionally, no specific provisions for data sharing were included in the original informed consent approved by the ethics committee.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Dec 2025, 7 months after the start.

Of 1,297 non-industry interventional studies with no phase under Chronic Pain, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 39. This study's planned 7 months is below that.

Counting every sponsor, half of 1,380 studies reached it within 20 months; a quarter within 9 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2025
First posted
Jun 26, 2025
StartActual
May 6, 2025
Primary completionEst.
Dec 2025
CompletionEst.
Jan 2026
Last update
Jun 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07038434
Lead sponsor
Valentina Cerrone
Collaborators
University of Salerno, Italy, Federico II University
Responsible party
Valentina Cerrone (Study Coordinator, Azienda Ospedaliera OO.RR. S. Giovanni di Dio e Ruggi D'Aragona) — Sponsor-investigator
First posted
Jun 26, 2025
Start date
May 6, 2025
Primary completion
Dec 2025 (estimated)
Completion
Jan 2026 (estimated)
Last update
Jun 26, 2025

Study contacts

Marco Cascella, MD, PhD
Contact
mcascella@unisa.it
+39 089 672428
Valentina Cerrone, RN, MSc
Contact
valentina.cerrone@sangiovannieruggi.it
Marco Cascella, MD, PhD
principal investigator · University of Salerno

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion